tbuckley/cabot-search huggingface dataset:
Ligue Europeenne contre le Rhumatisme: General Meeting, 1957
Authors: P Barcel6, K Gotsch
Journal: Annals of the Rheumatic Diseases (1957)

into implanted plastic sponges are the criteria used.A series of sulphonamides, antimalarial, antibiotics, corti- sone, and phenylbutazone are all compared at a single arbitrary dose level, and by this method all these sub- stances appear to have a somewhat similar effect.This is followed by some experimental studies of adrenal atrophy in rats after steroid administration and accounts of the clinical use of prednisone in various rheumatic diseases.Professor Coste himself contributes an excellent article on the early symptoms and signs of rheumatoid arthritis, and Dr. Piguet gives a good account of the radiological and clinical features of rheumatoid arthritis of the hip, an important and much neglected subject.There is a series of chapters on what are described as dermato-rheumatic syndromes, such as dermatomyositis, scleroderma, systemic lupus erythematosus, and the non- suppurative panniculitis of Weber-Christian.Among others there are good chapters on scolioses, achondro- plasia, and also the sacro-iliac joint in adolescents.It is a pity in some ways that these volumes are so heterogeneous, but they certainly provide an excellent guide to the experience and the views of our French colleagues and are most valuable.
Phase I dose escalating study of PEG-PGA and DON: A new amino acid depleting anti cancer drug approach
Authors: C. Unger, R. Harzmann, C. Müller, C. Witt, J. Roberts, N. Sethuraman
Journal: Journal of Clinical Oncology (2005)

3130 Background: To meet the increased demand arising from dependence on and decreased intracellular pool of glutamine, tumor cells have in general an upregulated uptake mechanism for glutamine. The rational for using a glutamine antimetabolite 6-diazo-5-oxo-L-norleucine (DON) in combination with PEGylated glutaminase (PEG-PGA) is based on the premise that the effectiveness of DON will be enhanced when the available pool of glutamine is strongly depleted by the enzyme. Methods: In the second step of this phase I study patients with various advanced solid tumors were treated with 120 I.U./m2 of PEG-PGA which was optimized in first step of the study in combination with an increasing dose level of DON. PEG-PGA (15 min i.v. infusion) and DON (10 min i.v. infusion) were administered twice a week. DON was administered four hours after PEG-PGA infusion at levels of 5mg/m2(n=3), 10mg/m2(n=3), 16mg/m2(n=3), 25mg/m2(n=12), 35mg/m2(n=3), 45mg/m2(n=5). Results: 65.5% of the 29 treated patients in the second step of this study had a Karnofsky index of greater than 90%. Median Age of the patients in the clinical trial was 63 (range 43–71) and 58.6% of the patients were male. Overall 259 courses have been administered with a median of seven courses per patient (range 4–19). At the 25mg/m2 dose level CTC3 nausea and vomiting were observed in three patients. After a sufficient antiemetic therapy was initiated to each dosing of DON no further CTC3 nausea and vomiting were reported. One Patient has shown CTC3 allergic reaction and another patient has shown transient CTC3 visioning which was probably not drug related. No CTC2–4 hematological toxicities were observed. In the first five dose levels five patients showed a stable disease at 10mg/m2(n=1), 25mg/m2 (n=3) and 35 mg/m2 (n=1) from 2 to 10 months. One patient with colorectal cancer showed a decline of the CEA marker from 170ng/ml to 17ng/ml Conclusions: The combination of PEG-PGA and DON is well tolerated. DLT has not been reached yet. Further dose escalation of DON is ongoing. No significant financial relationships to disclose.
Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer.
Authors: Dylan Michael Zylla, Michael Kuskowski, Kiran Allam, Pankaj Gupta
Journal: Journal of Clinical Oncology (2014)

e20631 Background: Pain is an independent prognostic factor for overall survival (OS) in non-small cell lung cancer (NSCLC). In in vitro and pre-clinical experiments, opioids promote angiogenesis and accelerate tumor growth and metastases. Opioid receptors are expressed in human NSCLC. Morphine stimulates proliferation and invasiveness of NSCLC cell lines by cross-activation of EGFR and other signaling pathways. Methods: To examine if long-term opioid requirement, independently of chronic pain, is associated with survival, we analyzed 209 patients diagnosed with stage IIIB/IV NSCLC at the Minneapolis VA and treated with chemotherapy. Pain was stratified by the proportion of time a patient reported severe pain (level 7-10 on a scale of 0-10; high pain (HP): ≥10% of the time, low pain (LP): <10% time). Opioids were converted to oral morphine equivalents (OME) (high opioid (HO): ≥5mg OME/day, low opioid (LO): <5mg OME/day). To separate pain levels from opioid exposure for analysis, four subgroups were created based on pain and opioid levels: LPLO, LPHO, HPLO and HPHO. The effects of pain, opioid requirement, and known prognostic variables on outcomes were analyzed in univariable and multivariable models. Results: Severe pain prior to chemotherapy initiation was associated with shorter OS (HR 1.39, 95% CI 1.02 - 1.87, p=0.035). Both high pain levels and high opioid requirement in the first 90 days after starting chemotherapy were strongly associated with shorter OS on univariable analysis. Remarkably, patients in the LPLO group during the first 90 days after starting chemotherapy had nearly 12 months longer median survival compared to the other 3 groups (17.9 months vs. 5.7 months (HPLO), 6.5 months (LPHO), and 6.2 months (HPHO), log-rank p=0.002). In multivariable models, longer survival in the LPLO group was sustained after adjustment for age, stage and performance status. Conclusions: Though usually related to each other, both higher chronic cancer-related pain levels and greater long-term opioid requirement are independently associated with shorter survival in advanced NSCLC. Prospective investigation of pain and opioid requirement is warranted to determine if opioid-sparing approaches improve outcomes.
Efficiency of Female Mammary Gland.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review The Pituitary Gland: An investigation of the most recent advances The proceedings of the Association for Research in Nervous and Mental Disease, New York, December 28 and 29, 1936 . Edited by Walter Timme, Angus M. Frantz and Clarence C. Hare. 764 pp. Baltimore: Williams &amp; Wilkins Company, 1938. $10.00.
Journal: New England Journal of Medicine (1938)
THE PHARMACOPEIA AND THE PHYSICIAN.CHAPTER XI.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Centers for Disease Control and Prevention. Impact of the expanded AIDS surveillance case definition on AIDS case reporting--United States, first quarter, 1993
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TYPHUS IN UNITED STATES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prion protein attenuates excitotoxicity by inhibiting NMDA receptors
Authors: Houman Khosravani, Yunfeng Zhang, Shigeki Tsutsui, Shahid Hameed, Christophe Altier, Jawed Hamid, Lina Chen, Michelle Villemaire, Zenobia Ali, Frank R. Jirik, Gerald W. Zamponi
Journal: The Journal of Experimental Medicine (2008)
National Preparedness Month — September 2015
Authors: Tracy Thomas, Michelle Leander-Griffith, Victoria Harp, Joan Cioffi, Thomas Frieden, Harold Jaffe, Joanne Cono, Chesley Richards, Michael Iademarco, Sonja Rasmussen, Charlotte Kent, Jacqueline Gindler, Acting Editor, Teresa Rutledge, Douglas Weatherwax, Teresa Hood, Jude Rutledge, Martha Boyd, Maureen Leahy, Julia Martinroe, Stephen Spriggs, Brian Wood, Quang Doan, Phyllis King, Teresa Moreland, Terraye Starr, Timothy Jones, Matthew Boulton, Ann Arbor, Virginia Mi, Jonathan Caine, Los Fielding, David Angeles, William Fleming, King Halperin, Rima Khabbaz, Patricia Quinlisk, Patrick Remington, William Roper, William Schaffner, Kathleen Attfield, Christine Dobson, Jennifer Henn, ; Meileen Acosta, Svetlana Smorodinsky, Jason Wilken, Tracy Barreau, Merritt Schreiber, Gayle Windham, Barbara Materna, Rachel Roisman, Kathryn Arnold
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Throughout September, CDC and more than 3,000 organizations (including national, regional, and local governments, as well as private and public institutions) will support emergency preparedness efforts and encourage U.S. residents to take action to become more prepared for emergencies.For Preparedness Month 2015 (1), CDC's Office of Public Health Preparedness and Response plans to focus on the importance of community resilience.A resilient community is one that can withstand, adapt, and quickly recover from events while minimizing negative health impacts.Building a strong, resilient community requires preparedness efforts at all levels, starting at home with the family, and expanding to include neighborhoods, workplaces and schools, travel plans, and online communities.Following the theme of community resilience, CDC's Public Health Matters (2) blog will feature stories about sheltering with children, Los Angeles County discussions on community preparedness, a medication dispensing exercise in Virginia, a world traveler's take on preparedness when on the move, and a look at using online networks in emergencies.Preparedness Month will also feature the release of the reports in this issue of MMWR, infographics, social media messages, and a Twitter Chat on community resilience on September 16.The month will culminate in the PrepareAthon's National Day of Action (3) on September 30.
The Authors Reply
Authors: Vivek Kumar, Vivekanand Jha
Journal: Journal of the American Society of Nephrology (2018)

We thank Dr. Nwaohiri1 for commenting on our work and agree with the statement that the jury is still out about the consistency of the effect of vitamin D supplementation on vascular function in CKD. Vascular disease in CKD is multifactorial, and the effect of a single intervention will be affected by a variety of patient-related factors as well as study-related factors. Some important differences between our study and the study by Kendrick et al.2 could explain the differential findings. In addition to a younger population, a lower proportion of smokers, and exclusion of patients with diabetes, our population was more vitamin D deficient (13.2±4.8 ng/ml [placebo] and 13.4±4.4 ng/ml [cholecalciferol] in our study versus 21.7±7.7 ng/ml [calcitriol] and 23±7.6 ng/ml [cholecalciferol] in the study by Kendrick et al.2) and received a higher cholecalciferol dose (5000 versus 2000 IU/d). Importantly, the rise in 25(OH)D and the final achieved levels were greater in the group that received cholecalciferol in our study (mean change: 24.9 versus 11 ng/ml). Furthermore, Kendrick et al.2 did not notice any change in another important biologic effect of vitamin D: that on parathyroid hormone. It can be speculated that the rise in circulating 25(OH)D level was not enough to lead to significant biologic effect. Although the uncertainty about the effect of vitamin D on vascular end points remains, evidence in favor of the beneficial effect of correcting vitamin D deficiency in CKD—including the positive effect on cardiovascular health—is growing. Observational studies and clinical trials have documented favorable modulation of vascular and endothelial function after supplementation with native or activated forms of vitamin D.3,4 In our study, the cholecalciferol-treated patients also experienced a favorable decrease in pulse wave velocity. Similar results were reported in another recent randomized, placebo-controlled clinical trial.5 In this study, patients who achieved the highest 25(OH)D levels were the ones with greatest decreases in pulse wave velocity. Also worth noting is that vitamin D supplementation has been generally safe. Rather than persist with the one size fits all approach, studies are needed to figure out appropriate patient populations, optimal threshold, preferred formulation, and dose and target levels for vitamin D supplementation and evaluate the effects on hard cardiovascular end points so that our patients can derive the benefits from correction of the vitamin D deficiency. Disclosures None.
Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis
Authors: M. Siegel
Journal: JAMA (1966)

A prospective study on maternal virus diseases occurring from 1957 through 1964 disclosed an increase in frequency of prematurity following hepatitis, measles, and rubella. The occurrence of low birth weight was largely related to retarded intrauterine growth following rubella, and to premature onset of labor in hepatitis and measles. Data for mumps and chickenpox in mothers revealed no association with prematurity. There appeared to be no significant difference in the virulence of rubella virus prevalent in epidemic and nonepidemic years as determined by the frequency of low birth weight. These results agree with those previously reported for fetal deaths in the same affected population. In a study of maternal virus diseases, an interrelationship between prematurity and other fetal effects of maternal infection, such as fetal death and congenital defects, was found.
Utilization of sperm banking in young men undergoing chemotherapy for testis cancer.
Authors: Mary J. Brames, Somer Case-Eads, Lawrence H. Einhorn
Journal: Journal of Clinical Oncology (2014)

e20586 Background: Testicular cancer (T.C.) accounts for only 1% of male malignancies, but is the most common carcinoma in 15-35-year-old patients. 80% with metastases achieve disease-free status with chemotherapy +/- surgical resection of residual disease. Standard first-line chemotherapy is BEP (bleomycin, etoposide, cisplatin) for 3-4 courses or EP for 4 courses. 40% of patients receiving chemotherapy will have permanent oligospermia, or even azoospermia. Impaired spermatogenesis is related to chemotherapy. Sperm banking is an effective method of collecting and storing sperm for future fertility. However, it is costly and not routinely covered by insurance. Banking facilities may not be available, or sperm banking may not have been offered. This retrospective study was performed to assess whether sperm banking was done and if not, the reasons why. Methods: Charts were screened for eligibility at follow-up visits. Patients were given a 5-point questionnaire. Questions included: Did you bank sperm prior to chemotherapy? If yes, have you utilized the stored sperm? Did it result in multiple births? If you did not bank sperm, what was the deciding factor? a) not offered b) time constraints c) cost d) not interested e) other. Eligible patients > 18 years, 1 year post-chemotherapy and able to complete the questionnaire. Results: 159 patients completed the questionnaire. Age range of 18 to 63 years. 105 patients (66%) did not bank sperm, 30 were not offered sperm banking, 24 of those due to advanced disease. 11 patients were constrained due to cost and the rest declined, most stating they had children and not interested in further progeny. 54 patients chose to bank sperm. 13 utilized their banked sperm with 9 successful pregnancies, including 3 multiple births. Conclusions: Sperm banking should be offered to testicular cancer patients when feasible and reasonable. This study will help identify barriers to routine utilization of sperm banking pre-chemotherapy.
The European Community Respiratory Health Survey II
Journal: European Respiratory Journal (2002)

The European Community Respiratory Health Survey (ECRHS) II will determine the incidence of and risk factors for the development of allergic disease, atopy and rapid loss of lung function in middle-aged adults living in Europe. From 1991–1993, &gt;18,000 individuals took part in ECRHS I and provided information on symptoms and exposure to known or suspected risk factors for asthma. Blood samples for assessment of specific immunoglobulin E to environmental allergen were taken and lung function and bronchial responsiveness to methacholine were assessed. From 1999–2001, study participants were re-contacted to determine symptom status and exposure to a variety of factors, including tobacco smoke, animals, occupational agents and air pollutants (including particulate matter). In a subsample of responders, exposure to house dust-mite allergen was assessed by analysis of dust samples taken from participants9 mattresses. In addition, blood samples suitable for deoxyribonucleic acid extraction were collected and stored. Currently, European Community Respiratory Health Survey II is being conducted in 29 centres in 14 countries. At the time of writing this paper, 27 centres had begun the study and ∼12,000 participants had completed a short postal questionnaire, ∼9,000 had completed a more detailed health assessment and 3,500 participants had provided dust samples. Historical air-pollution data have been collated and the programme of monitoring particles with a 50% cut-off aerodynamic diameter of 2.5 µm has been completed in 21 centres in 10 countries.
Environment
Authors: Bond L. Boble
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal